Tivozanib + Sunitinib
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Renal Cell Carcinoma
Conditions
Metastatic Renal Cell Carcinoma
Trial Timeline
Jul 1, 2012 → Jan 1, 2014
NCT ID
NCT01673386About Tivozanib + Sunitinib
Tivozanib + Sunitinib is a phase 2 stage product being developed by Astellas Pharma for Metastatic Renal Cell Carcinoma. The current trial status is terminated. This product is registered under clinical trial identifier NCT01673386. Target conditions include Metastatic Renal Cell Carcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Renal Cell Carcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01673386 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic Renal Cell Carcinoma